vs
Side-by-side financial comparison of KKR Real Estate Finance Trust Inc. (KREF) and MACROGENICS INC (MGNX). Click either name above to swap in a different company.
MACROGENICS INC is the larger business by last-quarter revenue ($41.2M vs $25.8M, roughly 1.6× KKR Real Estate Finance Trust Inc.). On growth, MACROGENICS INC posted the faster year-over-year revenue change (113.0% vs -26.6%). Over the past eight quarters, MACROGENICS INC's revenue compounded faster (112.8% CAGR vs -18.8%).
KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.
MacroGenics Inc is a clinical-stage biopharmaceutical firm specializing in the research and development of novel immunotherapies for cancer and autoimmune disorders. Its core product pipeline centers on monoclonal antibody-based treatments, with key programs targeting solid tumors and hematological malignancies, supported by partnerships with global pharmaceutical partners.
KREF vs MGNX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $41.2M |
| Net Profit | $-26.2M | — |
| Gross Margin | — | — |
| Operating Margin | -105.1% | -29.3% |
| Net Margin | -101.7% | — |
| Revenue YoY | -26.6% | 113.0% |
| Net Profit YoY | -229.6% | — |
| EPS (diluted) | $-0.49 | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $41.2M | ||
| Q3 25 | $25.3M | $72.8M | ||
| Q2 25 | $30.2M | $22.2M | ||
| Q1 25 | $31.3M | $13.2M | ||
| Q4 24 | $35.1M | $19.4M | ||
| Q3 24 | $37.0M | $110.7M | ||
| Q2 24 | $40.4M | $10.8M | ||
| Q1 24 | $39.1M | $9.1M |
| Q4 25 | $-26.2M | — | ||
| Q3 25 | $13.8M | $16.8M | ||
| Q2 25 | $-29.7M | $-36.3M | ||
| Q1 25 | $-4.9M | $-41.0M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $-7.4M | $56.3M | ||
| Q2 24 | $25.8M | $-55.7M | ||
| Q1 24 | $-3.1M | $-52.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 98.8% | ||
| Q3 24 | — | 99.8% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 97.0% |
| Q4 25 | -105.1% | -29.3% | ||
| Q3 25 | 50.4% | 25.6% | ||
| Q2 25 | -101.3% | -165.3% | ||
| Q1 25 | -18.3% | -323.1% | ||
| Q4 24 | 55.8% | -273.0% | ||
| Q3 24 | -19.6% | 48.9% | ||
| Q2 24 | 63.3% | -538.9% | ||
| Q1 24 | -8.7% | -590.4% |
| Q4 25 | -101.7% | — | ||
| Q3 25 | 54.4% | 23.1% | ||
| Q2 25 | -98.5% | -163.0% | ||
| Q1 25 | -15.5% | -311.1% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -20.0% | 50.9% | ||
| Q2 24 | 63.9% | -515.6% | ||
| Q1 24 | -7.9% | -573.3% |
| Q4 25 | $-0.49 | $-0.23 | ||
| Q3 25 | $0.12 | $0.27 | ||
| Q2 25 | $-0.53 | $-0.57 | ||
| Q1 25 | $-0.15 | $-0.65 | ||
| Q4 24 | $0.22 | $-0.24 | ||
| Q3 24 | $-0.19 | $0.90 | ||
| Q2 24 | $0.29 | $-0.89 | ||
| Q1 24 | $-0.13 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.6M | $57.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $55.6M |
| Total Assets | $6.5B | $256.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.6M | $57.2M | ||
| Q3 25 | $204.1M | $80.1M | ||
| Q2 25 | $107.7M | $130.7M | ||
| Q1 25 | $106.4M | $145.6M | ||
| Q4 24 | $104.9M | $182.8M | ||
| Q3 24 | $108.8M | $179.6M | ||
| Q2 24 | $107.2M | $83.9M | ||
| Q1 24 | $106.5M | $80.4M |
| Q4 25 | $1.2B | $55.6M | ||
| Q3 25 | $1.2B | $67.0M | ||
| Q2 25 | $1.2B | $46.6M | ||
| Q1 25 | $1.3B | $79.1M | ||
| Q4 24 | $1.3B | $116.1M | ||
| Q3 24 | $1.4B | $120.1M | ||
| Q2 24 | $1.4B | $57.8M | ||
| Q1 24 | $1.4B | $106.2M |
| Q4 25 | $6.5B | $256.8M | ||
| Q3 25 | $6.5B | $270.8M | ||
| Q2 25 | $6.8B | $245.4M | ||
| Q1 25 | $6.6B | $224.6M | ||
| Q4 24 | $6.4B | $261.7M | ||
| Q3 24 | $6.8B | $264.5M | ||
| Q2 24 | $7.1B | $201.1M | ||
| Q1 24 | $7.3B | $248.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $72.3M | $43.0M |
| Free Cash FlowOCF − Capex | — | $42.8M |
| FCF MarginFCF / Revenue | — | 103.8% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-83.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $72.3M | $43.0M | ||
| Q3 25 | $18.5M | $-30.2M | ||
| Q2 25 | $21.1M | $-47.0M | ||
| Q1 25 | $15.9M | $-46.9M | ||
| Q4 24 | $132.6M | $-38.4M | ||
| Q3 24 | $49.1M | $60.2M | ||
| Q2 24 | $30.6M | $-44.5M | ||
| Q1 24 | $34.5M | $-45.6M |
| Q4 25 | — | $42.8M | ||
| Q3 25 | — | $-30.6M | ||
| Q2 25 | — | $-47.7M | ||
| Q1 25 | — | $-47.4M | ||
| Q4 24 | — | $-39.0M | ||
| Q3 24 | — | $59.6M | ||
| Q2 24 | — | $-45.5M | ||
| Q1 24 | — | $-47.1M |
| Q4 25 | — | 103.8% | ||
| Q3 25 | — | -42.0% | ||
| Q2 25 | — | -214.5% | ||
| Q1 25 | — | -359.5% | ||
| Q4 24 | — | -201.7% | ||
| Q3 24 | — | 53.8% | ||
| Q2 24 | — | -421.6% | ||
| Q1 24 | — | -517.4% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.0% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | 16.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.34× | -1.79× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.54× | — | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KREF
Segment breakdown not available.
MGNX
| Revenue From Collaborative Agreements | $20.3M | 49% |
| Contract Manufacturing | $11.3M | 27% |
| Other | $9.7M | 23% |
